Jan Stahlberg bought $7.6M of DMAC
owner at DiaMedica Therapeutics Inc.. 1,061,277 shares at an average of $7.19, traded Nov 17, 2025, filed Dec 8, 2025.
Score components
- +12Role10% owner
- +25Trade size$7.6M at market
- +3Relative to holdingsHoldings up 14%
- 0Price contextNo price history yet
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
- -5Outside holderA 10% owner who is not an officer or director
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -3.1%, 3m -11.1%, 6m -36.0%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001104659-25-119360, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 17, 2025 | POpen-market purchase Common Sharesindirect: See Footnote | +187,393 | $6.52 | $1.2M | 7,951,858 | Dec 8, 2025 |
| Nov 18, 2025 | POpen-market purchase Common Sharesindirect: See Footnote | +182,882 | $6.75 | $1.2M | 8,134,740 | Dec 8, 2025 |
| Nov 19, 2025 | POpen-market purchase Common Sharesindirect: See Footnote | +240,352 | $7.21 | $1.7M | 8,375,092 | Dec 8, 2025 |
| Nov 20, 2025 | POpen-market purchase Common Sharesindirect: See Footnote | +128,426 | $7.41 | $951k | 8,503,518 | Dec 8, 2025 |
| Nov 21, 2025 | POpen-market purchase Common Sharesindirect: See Footnote | +208,872 | $7.41 | $1.5M | 8,712,390 | Dec 8, 2025 |
| Nov 24, 2025 | POpen-market purchase Common Sharesindirect: See Footnote | +40,253 | $7.89 | $318k | 8,752,643 | Dec 8, 2025 |
| Nov 25, 2025 | POpen-market purchase Common Sharesindirect: See Footnote | +73,099 | $8.57 | $627k | 8,825,742 | Dec 8, 2025 |
Related signals
Other insiders at DiaMedica Therapeutics Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 40Moderate | DMACbuy DiaMedica Therapeutics Inc. | Jan Stahlberg owner | $6.0M 1,000,000 shares | +15% | |
| 57Moderate | DiaMedica Therapeutics Inc. | Thomas Von Koch owner | $10.0M 2,857,142 shares | +52% | |
| 53Moderate | DiaMedica Therapeutics Inc. | Jan Stahlberg owner | $5.4M 1,542,857 shares | +30% | |
| 50Moderate | DiaMedica Therapeutics Inc. | Richard Jacinto II owner | $1.4M 400,000 shares | +9% | |
| 64Notable | DiaMedica Therapeutics Inc. | Jan Stahlberg owner | $3.0M 1,200,000 shares | +30% | |
| 54Moderate | DiaMedica Therapeutics Inc. | Thomas Von Koch owner | $3.0M 1,200,000 shares | +28% | |
| 30Weak | DMACbuy DiaMedica Therapeutics Inc. | David J. Wambeke Chief Business Officer | $49k 20,000 shares | +4% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.